Sanara Medtech Inc (SMTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanara Medtech Inc (SMTI) has a cash flow conversion efficiency ratio of 0.665x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.95 Million) by net assets ($5.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Sanara Medtech Inc (SMTI) market capitalisation for the company's overall valuation and market capitalisation.
Sanara Medtech Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Sanara Medtech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Sanara Medtech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanara Medtech Inc ranked by their cash flow conversion efficiency. Explore SMTI operating cash flow to net income to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tai-Saw Technology Co Ltd
TWO:3221
|
0.026x |
|
Mega Uranium Ltd.
TO:MGA
|
-0.005x |
|
POLARIS RENEWABLE ENERGY
F:N4T
|
N/A |
|
HealWELL AI Inc.
TO:AIDX
|
-0.003x |
|
Enad Global 7 AB
ST:EG7
|
0.015x |
|
AGV Products Corp
TW:1217
|
0.017x |
|
Westwood Holdings Group Inc
NYSE:WHG
|
-0.020x |
|
Michlol Finance Ltd
TA:MCLL
|
-0.410x |
Annual Cash Flow Conversion Efficiency for Sanara Medtech Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Sanara Medtech Inc from 1999 to 2025. View SMTI live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.93 Million | $6.79 Million | 1.145x | +187346.65% |
| 2024-12-31 | $38.91 Million | $-23.78K | -0.001x | +99.16% |
| 2023-12-31 | $44.59 Million | $-3.25 Million | -0.073x | +45.33% |
| 2022-12-31 | $41.72 Million | $-5.55 Million | -0.133x | +16.61% |
| 2021-12-31 | $30.15 Million | $-4.81 Million | -0.160x | +76.89% |
| 2020-12-31 | $5.84 Million | $-4.03 Million | -0.691x | -103.74% |
| 2019-12-31 | $6.39 Million | $-2.17 Million | -0.339x | -236.05% |
| 2018-12-31 | $1.11 Million | $277.14K | 0.249x | +118.27% |
| 2017-12-31 | $102.54K | $-139.86K | -1.364x | -41.01% |
| 2016-12-31 | $-423.07K | $409.25K | -0.967x | -202.23% |
| 2015-12-31 | $-1.27 Million | $-1.20 Million | 0.946x | -53.70% |
| 2014-12-31 | $-825.40K | $-1.69 Million | 2.043x | +176.87% |
| 2013-12-31 | $-2.47 Million | $-1.82 Million | 0.738x | +129.08% |
| 2012-12-31 | $-3.81 Million | $-1.23 Million | 0.322x | +261.94% |
| 2011-12-31 | $-3.86 Million | $-343.60K | 0.089x | +117.11% |
| 2010-12-31 | $2.87 Million | $-1.49 Million | -0.520x | +7.01% |
| 2009-12-31 | $2.31 Million | $-1.30 Million | -0.560x | -116.99% |
| 2008-12-31 | $-321.26K | $-1.06 Million | 3.295x | +1468.87% |
| 2007-12-31 | $-1.81 Million | $-380.90K | 0.210x | -33.10% |
| 2006-12-31 | $-1.27 Million | $-398.97K | 0.314x | -67.45% |
| 2005-12-31 | $-647.47K | $-624.45K | 0.964x | +107.24% |
| 2004-12-31 | $41.20K | $-548.46K | -13.313x | -3955.33% |
| 2001-12-31 | $-2.10 Million | $-723.86K | 0.345x | -16.37% |
| 2000-12-31 | $-1.38 Million | $-569.36K | 0.413x | -75.18% |
| 1999-12-31 | $-377.38K | $-627.86K | 1.664x | -- |
About Sanara Medtech Inc
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and seco… Read more